Tang Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Tang Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-200,825	Closed	-$104K	–	205
2024 Q4	$104K	Buy	200,825 +150,000	+295%	+$366K	0.01%	182
2024 Q3	$165K	Sell	50,825 -187,049	-79%	-$606K	0.01%	150
2024 Q2	$714K	Buy	237,874 +237,492	+62,171%	+$859K	0.07%	99
2024 Q1	$1.78K	Buy	+382	New	+$1.84K	﹤0.01%	99
2023 Q1	–	Sell	-100,000	Closed	-$349K	–	119
2022 Q4	$349K	Sell	100,000 -300,000	-75%	-$2.63M	0.05%	81
2022 Q3	$14.8M	Hold	400,000	–	–	1.82%	18
2022 Q2	$7.6M	Buy	+400,000	New	+$8.72M	1.15%	23
2022 Q1	–	Sell	-59,122	Closed	-$1.33M	–	55
2021 Q4	$1.33M	Sell	59,122 -40,878	-41%	-$909K	0.27%	28
2021 Q3	$2.62M	Hold	100,000	–	–	0.54%	18
2021 Q2	$3.2M	Sell	100,000 -100,000	-50%	-$3.47M	0.64%	15
2021 Q1	$7.04M	Hold	200,000	–	–	1.98%	8
2020 Q4	$6.41M	Sell	200,000 -300,000	-60%	-$10.3M	0.98%	8
2020 Q3	$18.8M	Hold	500,000	–	–	3.4%	8
2020 Q2	$22.4M	Sell	500,000 -800,000	-62%	-$33.8M	2.18%	9
2020 Q1	$44.3M	Hold	1,300,000	–	–	6.23%	2
2019 Q4	$50.7M	Buy	+1,300,000	New	+$39.5M	6.06%	4

Other funds holding RLMD

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Tang Capital Management's RLMD Position: Q1 2025 in Review

Tang Capital Management sold out of Relmada Therapeutics (RLMD) in Q1 2025, closing a stake of 200,825 shares — an estimated $104K sold.

Tang Capital Management first reported a position in RLMD in Q4 2019 and held it in 16 quarters. The position peaked at $50.7M in Q4 2019. 44 funds tracked by Wall St. Rank hold RLMD as of Q1 2025.

Tang Capital Management reported no remaining Relmada Therapeutics position as of Q1 2025 after selling out during the quarter.
Tang Capital Management sold 200,825 Relmada Therapeutics shares in Q1 2025, an estimated $104K.
Tang Capital Management first reported a position in Relmada Therapeutics in Q4 2019 and held it in 16 quarters.
Tang Capital Management's Relmada Therapeutics position peaked at $50.7M in Q4 2019.
44 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2025.

Based on Tang Capital Management's 13F filing for Q1 2025, filed 15 May 2025.